Wedbush Research Analysts Cut Earnings Estimates for YMAB
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Investment analysts at Wedbush lowered their Q1 2025 earnings per share estimates for shares of Y-mAbs Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.23) for […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Investment analysts at Wedbush lowered their Q1 2025 earnings per share estimates for shares of Y-mAbs Therapeutics in a research report issued to clients and investors on Tuesday, March 4th. Wedbush analyst D. Nierengarten now forecasts that the company will post earnings per share of ($0.23) for […]
